Case series demonstrates clinical and serologic improvements in refractory autoimmune disease, suggesting BCMA-directed rescue therapy is effective.
Teclistamab, a T-cell engager targeting B-cell maturation antigen, showed promise as a rescue therapy in 10 patients with refractory autoimmune diseases and led to clinical and serologic improvements in most patients.
No takes yet. Share an insight, caveat, or question.
Bucci et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: